Linda Barkāne

Telomere length and mitochondrial DNA copy number in multidrug-resistant tuberculosis.

R. Ranka, E. Zole, Agnija Kivrane, 2021, Tuberculosis.

Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.

A. Benedetti, D. Falzon, P. Nahid, 2020, The Lancet. Respiratory medicine.

Assessment of Amikacin- and Capreomycin-Related Adverse Drug Reactions in Patients with Multidrug-Resistant Tuberculosis and Exploring the Role of Genetic Factors

R. Ranka, Agnija Kivrane, Lauma Freimane, 2023, Journal of personalized medicine.

Safety and efficacy of exposure to bedaquiline−delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia

Y. Yazdanpanah, E. Caumes, N. Veziris, 2018, European Respiratory Journal.

Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study

S. Heysell, G. Sotgiu, Simon Tiberi, 2020, BMJ Open.

Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens

N. Hittel, R. Gupta, L. Kukša, 2017, European Respiratory Journal.